[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100527687":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":33,"collaborators":36,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":41,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":53,"studyType":54,"phases":7,"briefSummary":55,"conditions":56,"keywords":7,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"University College London Hospitals","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Orla Mitchell","CONTACT","020 801 68413","pdfrontline@ucl.ac.uk",[15],{"facility":16,"status":17,"city":18,"state":7,"zip":19,"country":20,"countryCode":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":28},"University College London (UCL)","RECRUITING","London","NW3 2PF","United Kingdom","UK",{"type":23,"coordinates":24},"Point",[25,26],-0.12574,51.50853,{"lat":26,"lon":25},[29,30],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"name":31,"role":32,"phone":7,"phoneExt":7,"email":7},"Tony Schapira","PRINCIPAL_INVESTIGATOR",{"type":32,"investigatorFullName":34,"investigatorTitle":35,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Anthony Schapira","Professor Anthony Schapira",[37],{"name":38,"class":6},"Cure Parkinson's","100527687","pd-frontline-part-of-rapsodi-gd-remote-assessment-of-people-with-parkinsons-100527687",false,"NCT06151002","PD Frontline (Part of RAPSODI GD) Remote Assessment of People With Parkinson's","PD Frontline, Part of RAPSODI GD (Remote Assessment of Parkinsonism Supporting Ongoing Development of Interventions in Gaucher's Disease) to Build an Online Trial-ready Cohort of GBA Genotyped People With Parkinson's","PD Frontline","Inclusion Criteria:\n\n* Formal diagnosis of Parkinson Disease\n\nExclusion Criteria:\n\n* Confirmation that the individual carries a GBA variant (GBA positive). These individuals will be referred to sister-study, RAPSODI.\n* History of Parkinsonism (progressive supranuclear palsy, multiple system atrophy, traumatic, manganese toxicity, postencephalitic, vascular PD; drug induced PD; corticobasal degeneration)\n* Individuals with another neurological disorder including: dementia, movement disorders, and motor neurone disease.\n* Individuals on drugs known to be associated with parkinsonism, including neuroleptic agents (Amisulpride, Chlorpromazine Hydrochloride, Flupenthixol, Fluphenazine Hydrochloride, Haloperidol, Methotrimeprazine, Levomepromazine, Olanzapine, Oxypertine, Pericyazine, Perphenazine, Pimozide, Pipotiazine, Prochlorperazine, Promazine Hydrochloride, Reserpine, Risperidone, Sulpiride, Thioridazine, Trifluoperazine, Zuclopenthixol acetate, Zotepine), plus Bupropion, , Lithium, Methyldopa, Metoclopramide and Sodium Valproate).","ALL","18 Years","90 Years",{"count":51,"type":52},4800,"ESTIMATED","20 Years","OBSERVATIONAL","PD Frontline (part of RAPSODI GD) is an online study observational study with the goal of bringing People with Parkinson's to the frontline of research by getting them trial ready. To do this, participants are offered genetic sequencing for the GBA and LRRK2 gene with an at-home saliva collection kit.",[57],"Parkinson Disease","2023-11-28",{"date":60,"type":61},"2023-11-30","ACTUAL",{"date":63,"type":61},"2020-02-15",{"date":65,"type":52},"2040-08-20",{"name":5,"class":6},1]